Characteristics of the patients.
| Characteristics | n = 25 |
|---|---|
| Age, mean, yrs (SD) | 31 ± 8 |
| Female, n (%) | 23 (92) |
| Previous SLE manifestations | |
| Skin, n (%) | 14 (56) |
| Joints, n (%) | 12 (48) |
| Serous, n (%) | 4 (16) |
| Kidney, n (%) | 12 (48) |
| Central nervous system, n (%) | 1 (4) |
| SELENA-SLEDAI at Day 0, mean (range) | 2 (0–8) |
| Associated treatments at time of study | |
| Prednisone, n (%) | 17 (68) |
| Prednisone, median, mg/day (range) | 5 (0–15) |
| Hydroxychloroquine, n (%) | 21 (84) |
| Azathioprine, n (%) | 2 (8) |
| Mycophenolate mofetil, n (%) | 2 (8) |
SLE: systemic lupus erythematoaus; SELENA-SLEDAI: Safety of Estrogens in Lupus Erythematosus National Assessment - Systemic Lupus Erythematosus Disease Activity Index.